Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG. Show more
Location: 4224 Campus Point Court, San Diego, CA, 92121, United States | Website: https://www.regulusrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
565M
52 Wk Range
$0.83 - $8.35
Previous Close
$8.16
Open
$8.16
Volume
N/A
Day Range
$8.16 - $8.16
Enterprise Value
501M
Cash
65.37M
Avg Qtr Burn
-10.89M
Insider Ownership
2.71%
Institutional Own.
82.87%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|